1-3 of 3
Jeffrey Scott
Close
Sort by
Journal Articles

Siremadlin (HDM201) Is Well Tolerated and Demonstrates Clinical Activity in Patients with Acute Myeloid Leukemia Who Have Relapsed after Allogeneic Stem Cell Transplantation: A Subset Analysis of Safety and Preliminary Efficacy

Eytan M. Stein, Jörg Chromik, Cecilia Carpio, Rogier Mous, Jean-Jacques Kiladjian, Gheath Alatrash, Antonio Curti, Charles Craddock, Christoph Schmid, Robert Zeiser, Lamis K. Eldjerou, Hans-Jochen Jochen Weber, Claire Fabre, Jeffrey Scott, Daniel J. DeAngelo
Journal: Blood
Blood (2021) 138 (Supplement 1): 3417.
https://doi.org/10.1182/blood-2021-149751
Published: 2021
Journal Articles

The STIMULUS Program: Clinical Trials Evaluating Sabatolimab (MBG453) Combination Therapy in Patients (Pts) with Higher-Risk Myelodysplastic Syndromes (HR-MDS) or Acute Myeloid Leukemia (AML)

Amer M. Zeidan, MBBS, MHS, Jordi Esteve, Aristoteles Giagounidis, Hee-Je Kim, MD, PhD, Yasushi Miyazaki, MD PhD, Uwe Platzbecker, Andre C. Schuh, Mikkael A. Sekeres, Jörg Westermann, Zhijian Xiao, Kamel Malek, Jeffrey Scott, Julie Niolat, Severine Peyrard, Fei Ma, Flavia Kiertsman, Mario Stegert, Sabine Hertle, Pierre Fenaux, MD PhD, Valeria Santini
Journal: Blood
Blood (2020) 136 (Supplement 1): 45–46.
https://doi.org/10.1182/blood-2020-134718
Published: 2020
Journal Articles

Budget Impact Model for Hypomethylating Agent Use for the Treatment of Myelodysplastic Syndromes (MDS)

Bruce Feinberg, DO, Jeffrey Scott, MD, Susan Weidner, Barry Fortner, PhD
Journal: Blood
Blood (2008) 112 (11): 2397.
https://doi.org/10.1182/blood.V112.11.2397.2397
Published: 2008